-
HER2 exon 20 inserted mutation lung cancer (NSCLC) innovative drug! Pan-HER tyrosine kinase
Time of Update: 2023-01-01
The NDA seeks approval for poziotinib: a novel, oral, irreversible EGFR family receptor-blocking pan-HER inhibitor for the treatment of previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 exon 20 insertion mutations (Ex20ins).
-
From patient characteristics to treatment patterns, these MET exon 14 jumping mutation related studies on WCLC are worth a look!
Time of Update: 2022-11-15
*For medical professionals onlyThese studies from the WCLC can provide many valuable reference information for clinical diagnosis and treatment. The World Lung Cancer Conference (WCLC) is one of the m
-
The WU-KONG6 study was honored in the 2022 ESMO ESMO Sulvotinib Strength, Attacking the EGFR 20 Exon Insertion Mutation
Time of Update: 2022-10-13
In addition to this year's ESMO conference, suvotinib has previously reported 2-3 in the internationally renowned journal "Cancer Discovery" with a high impact factor and other influential international conferences (such as ASCO, WCLC), and the report of this ESMO conference once again confirms the broad application prospects of suvoltinib in the future, suggesting that it is expected to change the treatment pattern of EGFR 20 exon insertion mutation.
-
Mobozantinib is used in patients with positive EGFR exon 20 insertion mutations, significantly prolonging survival!
Time of Update: 2022-10-12
EGFR (Epidermal Growth Factor Receptor) is no stranger to cancer patients and is the most common driver gene for non-small cell lung cancer, especially in up to 60% of lung adenocarcinomas. EGFR mutat
-
Tracing the origin: How does the MET exon 14 skipping mutation cause cancer?
Time of Update: 2022-08-15
In recent years, targeted therapy has achieved great success in the treatment of non-small cell lung cancer (NSCLC) patients *For medical professionals only for reference Explore MET exon 14 skipping mutation in NSCLC!
-
Neurology: New achievements of the neurosurgery team of Peking University Tiantan Hospital - Exon
Time of Update: 2022-05-26
Other interesting genetic studies with smaller sample sizes have also identified several candidate genes for bAVM through triplet/family analysis or sequencing of individual cases .
Other interesting genetic studies with smaller sample sizes have also identified several candidate genes for bAVM through triplet/family analysis or sequencing of individual cases .
-
Front Oncol: Real-world data to explore treatment strategies and prognosis in patients with EGFR exon 18-mutated NSCLC
Time of Update: 2022-02-20
713483Xu H, Yang G, Li W, LiJ, Hao X, Xing P, Yang Y and Wang Y (2021) EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes .
-
Understanding Pulmonary Sarcomatoid Carcinoma: Jumping Mutations in Exon MET14 Brings New Ideas for Targeted Therapy
Time of Update: 2021-12-04
Returning to the study itself, the study included 70 patients with locally advanced or metastatic MET14 exon skip mutation positive and histological type of PSC or other NSCLC subtypes .
MET14 exon skipping mutation Research progress in non-small cell lung cancer[J].
-
Clin Cancer Res: Efficacy of adjuvant imatinib therapy in GIST patients with KIT exon 9 mutations: a European multicenter retrospective study
Time of Update: 2021-10-20
This retrospective study showed that GIST patients with KIT exon 9 mutations received adjuvant imatinib treatment, and a daily dose of 800 mg did not have a better survival prognosis than 400 mg a day .
-
J Clin Oncol: Efficacy and safety of Poziotinib in the treatment of advanced NSCLC with HER2 exon 20 mutation
Time of Update: 2021-09-29
Poziotinib is an innovative oral Broad-spectrum HER inhibitor, can irreversibly block the signal transmission of all HER family tyrosine kinase receptorsThis is a single-arm, open-label Phase 2 trial that evaluates the efficacy and safety of Bozitinib in advanced NSCLC patients with HER2 exon 20 mutations .
-
Takeda’s EXKIVITY™ (mobocertinib) became the first oral treatment approved by the US FDA for patients with EGFR exon 20 insertion + NSCLC
Time of Update: 2021-09-29
Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical Company Limited's, TSE: 4502 / NYSE: TAK ) (referred to as "Takeda") today announced that the US Food and Drug Administration Administration ( the FDA ) has approved during platinum-containing chemotherapy EXKIVITY (mobocertinib) for the treatment or Later , adult patients with locally advanced or metastatic non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (detected by FDA-approved testing) .
-
cell lung cancer with exon 20 insertion mutations: the results of the initial analysis of the phase I study CHRYSALIS
Time of Update: 2021-08-13
In summary, Amivantamab has shown good anti-tumor activity and safety in the treatment of platinum-based non-small cell lung cancer (NSCLC) patients with EGFR 20 exon insertion mutations .
-
Junshi Bio: EGFR exon 20 insertion and other rare mutation inhibitor JS111 was approved for trial
Time of Update: 2021-07-25
Uncommon EGFR mutations account for about 10% of all EGFR mutations, including EGFRexon 20 insertion, T790M primary point mutation and compound mutation, and G719X represented by the board of directors of the company and all directors guarantee that there is no content in this announcement.
-
Missing became the first drug approved to treat NSCLC with EGFR exon 20 insertion mutation!
Time of Update: 2021-06-30
The latest data of the Phase 1/2 clinical study based on mobocertinib's new drug application in the United States shows that in adult patients with metastatic NSCLC who have previously received platinum-containing chemotherapy, EGFR exon 20 insertion mutations, after more than one year (median Number: 14.
-
Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC
Time of Update: 2021-06-10
( TSE:4502/NYSE:TAK ) ("Takeda") today released mobocertinib (TAK-788) for oral treatment of epidermal growth factor receptor (EGFR) Exon 20 insertion mutation positive (insert+) metastatic non-small cell lung cancer (m NSCLC ) Phase 1/2 clinical trial data.
